23 results about "Trypanosoma sp" patented technology

Nucleoside analogues and compositions containing said nucleoside analogues are provided, according to a general formula (I) disclosed herein. Processes are provided for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the diagnosis, prevention and / or treatment of parasitic infections, more specifically for use in the diagnosis, prevention and / or treatment of a Trypanosoma infection.

The present invention provides diazo compounds having anti-trypanosomal activity, with less or no side-effects. The diazo compounds are structural analogue of quinapyramine and possess characteristics necessary for the targeted pharmacologic action of anti trypanosomosis, with reduced cytotoxicity. The compounds were found to have less cytotoxicity, and identical or better anti- parasitemia effect as compared to conventional quinapyramine sulfate.

The present invention relates to new specific 6-6 or 5-6 fused bicyclic compounds comprising pyrimidine or pyridine useful in the prevention and / or treatment of infectious diseases. In particular, the present invention relates to a compound of formula (I) wherein: Ar1 is a (C5-C11)arylene or (C5-C11)heteroarylene group, X is —CH—, —S—, —NR5 or —N—, Y is —CH—, —NR5—S— or —NR6—CH2—, T is —CH— and Q is —CH— or T is —N— and Q is —CR10— or —N—, provided that one or two of X, Q and Y comprise a heteroatom, and with the proviso that, at least one of R1, R2, and, if present, R5 or R6, contains a group —NH-Alk-NR3R4. The inventors showed that compounds of formula (I) present an activity against both W2 and 3D7 Plasmodium falciparum strains, an activity against T. brucei brucei but also an activity against SARS-CoV-2 virus, and that they are positive for G4 recognition. The invention also relates to the preparation process and to the therapeutic uses of the compounds of formula (I).

The invention discloses a method for prolonging the half-life period of polypeptide by introducing composite N-glycosylation modification, which comprises the following steps: expressing trypanosoma buchneri-derived oligosaccharyl transferase TbSTT3A in insect cells; the method comprises the following steps: synthesizing a mutant GLP-1M containing asparagine by using GLP-1; oligosaccharide in the humanized compound fatty alcohol oligosaccharide is transferred to GLP-1M by utilizing the catalysis of oligosaccharyl transferase TbSTT3A, so that the humanized compound N-glycopeptide with prolonged half-life period is obtained. According to the invention, a conventional complex in-vivo human N-carbohydrate chain biosynthesis pathway is broken, fatty alcohol oligosaccharide containing a human compound N-carbohydrate chain is synthesized in vitro, oligosaccharyl transferase TbSTT3A with high substrate adaptability is used for catalysis, and the compound N-carbohydrate chain is transferred from the fatty alcohol oligosaccharide to GLP-1M polypeptide, so that the stability of GLP-1M is remarkably enhanced, and the human N-carbohydrate chain-containing fatty alcohol oligosaccharide-GLP-1M can be used for preparing the GLP-1M-GLP-1M-GLP-1M-GLP-1M-GLP-1M-GLP-1M-GLP-1M. And a new strategy for prolonging the half-life period of the GLP-1 is provided.

The invention relates to the field of veterinary protozoology and methods for producing antigens, particularly for the diagnosis of Surra Su-Auru in animals. The objective of the invention is to develop a method for producing a highly sensitive trypanosomal antigen for the serological diagnosis of Surra (Su-Auru) in animals. The problem is solved by the fact that the method for obtaining trypanosome antigen for serological diagnostics of Surra (Su-Auru) in animals involves infecting rabbits intratesticularly with live trypanosomes of the T species. evansi, removal of the spleen 2-3 days after infection, total bleeding 8-10 days after splenectomy (parasitemia -80-90%), blood is collected in a wide vessel with 2% sodium citrate in physiological solution with constant stirring with a glass rod, at the rate of 1 part blood to 2 parts solution, settling of citrated blood in the refrigerator for 18-24 hours, centrifugation and separation of the middle layer from the sediment from the supernatant, 2-3 times washing of trypanosomes in physiological solution, at 3000-5000 rpm, for 10 minutes each, disintegration of the centrifugate by ultrasound at a frequency of 22 kHz, power of 60 W / cm2 for 8-12 minutes, followed by centrifugation of the disintegrate at 8000-10000 rpm for 20-30 minutes and collection of sediment (endoantigen), treatment of the supernatant with TCA, collection of the precipitated sediment (exoantigen), batches of sediment are mixed 10:1. The technical result provided by the utility model is expressed in the development of a method for obtaining a highly sensitive trypanosomal antigen for the serological diagnosis of Surra (Su-Auru) in animals.

The present invention relates to the use of an oligosaccharyl transferase (OST) enzyme obtained from Trypanosoma brucei to improve the expression of a functional and stable recombinant protein in a mammalian expression system. In particular, the present invention provides a mammalian cell comprising at least one nucleic acid sequence encoding at least one OST protein or a functional fragment thereof wherein at least one OST protein is a trypanosomes OST protein, preferably wherein at least one OST protein is a trypanosomes buchneri OST protein.

The present invention relates to the production of beneficial molecules in vivo using genetically modified non-pathogenic microorganisms. The invention can be applied to various fields such as medicine, human performance and veterinary medicine. In various embodiments, the use of a non-pathogenic microorganism transgenic trypanosoma rangeli can be purposefully engineered, altered, and designed such that it, after genetic modification, becomes a blood symbiont in humans and animals to express foreign nucleic acid sequences encoding proteins, polynucleotides, and / or pathways, such as proteins, polynucleotides, and / or pathways. Thereby treating a disease or enhancing specific aspects of host physiology, including the metabolic advantage of correcting or enhancing homeostatic imbalance in appropriate cases. The foreign nucleic acid sequences can be used to generate enzymes, scavenger molecules, peptides and hormones, antibodies, nanoantibodies, signaling ligands, and other therapeutic agents or novel synthetic agents.

The purpose of the present invention is to provide a novel enzyme for ketone body measurement that, unlike 3-hydroxybutyrate dehydrogenase, does not require NAD, which has low thermal stability, and therefore does not require a substance for reoxidizing NADH. The novel enzyme according to the present invention is a 3-hydroxybutyrate oxidase that is derived from a microorganism selected from the group consisting of microorganisms belonging to the genus Achromobacter, microorganisms belonging to the genus Pseudomonas, microorganisms belonging to the genus Trypanosoma, and microorganisms belonging to the genus Nocardia and has a physicochemical property of catalyzing a reaction for producing hydrogen peroxide by acting on D-3-hydroxybutyric acid, or is a 3-hydroxybutyrate oxidase that comprises an amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 7, or a sequence similar thereto.

The presently disclosed subject matter provides a method and pharmaceutical composition for long-term use in treating or preventing disease conditions caused by the parasite Trypanosoma cruzi known as Chagas disease. The pharmaceutical composition is a long-term injectable composition that can include a dose of Itraconazole and a dose of Amiodarone in an amount effective to treat Chagas disease, or in an amount effective to prevent Chagas disease in a human or animal patient such as a mammal. The pharmaceutical composition may also include a pharmaceutically acceptable vehicle, carrier, or excipient. The form of itraconazole used in the pharmaceutical composition may be prepared by any suitable process wherein the active ingredients to have sufficient bioavailability when injected into a human or animal subject. The long-term method for treating or preventing Chagas disease is carried out by a single injection of Itraconazole and Amiodarone in an amount effective to treat a subject in need thereof, and / or in an amount effective to prevent the subject from contracting the disease so that repeated dosages are not required again for a long-term period such as 6 or 12 months. The present compositions, methods, and uses are safer and longer lasting, more patient friendly, and provide a safer and more effective way of treating or preventing Chagas disease than previously possible.

The application belongs to the technical field of biotechnology, and particularly relates to a recombinant antigen of American trypanosomiasis and a preparation method and application thereof. The application provides a recombinant antigen of American trypanosomiasis, wherein a plurality of neutralizing epitopes and complete amino acid sequences of Trypanosoma cruzi antigens are connected according to a specific order to construct a recombinant antigen capable of covering all stages of the life cycle of Trypanosoma cruzi. The recombinant antigen is complete in Chagas antibody recognition site coverage, can recognize and combine all types of antibodies in the Chagas chronic and acute infection period, and is not easily interfered by other substances in serum, and is high in specificity.

Compositions, methods, and kits for stable Trypan Blue solutions are provided. In one example, a method includes: cooling a solution of Trypan Blue; and filtering the cooled solution. In another example, a method includes: mixing a water-soluble polymer with a Trypan Blue solution. The method may further include adding one or more ingredients such as an aqueous buffer, an osmolyte, an acid, a base, a buffer, a cell culture medium, water, or combinations thereof.

The invention belongs to the technical field of molecular biology and medical detection, and discloses a universal trypanosomes detection primer pair and a digital PCR detection method. According to the invention, two pairs of high-specificity universal primers are designed based on highly conserved 18S rRNA sequences among trypanosomes, and the sequences are shown as SEQ ID NO: 1-2 or SEQ ID NO: 12-13. Meanwhile, the invention provides an optimized digital PCR detection method, and the detection sensitivity and specificity are remarkably improved by accurately optimizing key parameters such as annealing temperature and primer concentration. Experiments prove that the system can stably detect a whole blood simulation sample with the trypanosomes content as low as 5 / ml or a trypanosomes sample with the DNA content as low as 0.01 pg (single reaction system), and the detection limit can reach a single copy level. The invention provides a powerful technical tool for early diagnosis, precise medication guidance and epidemiological monitoring of trypanosomiasis.

The invention discloses a trypanosoma multiplex fluorescence PCR nucleic acid detection kit and a quality control product based on artificial chromosome engineering bacteria, and belongs to the field of molecular biology. The kit comprises a specific primer probe group of trypanosoma krei and trypanosoma buchneri and other PCR reaction system components, and can realize high-specificity, high-sensitivity and high-accuracy typing detection of target genes of the two trypanosoma krei and the trypanosoma buchneri. The quality control strain is used for integrating a trypanosoma kirscheri minirepeat gene consistency sequence and a trypanosoma buchneri minirepeat gene consistency sequence into an escherichia coli artificial chromosome through a homologous recombination technology; according to the present invention, the cell structure of the engineering bacteria is retained, the nuclease degradation resistance is provided, the stability is high, the real sample extraction characteristic can be simulated, and the establishment of the fluorescent PCR and digital PCR quantitative detection gradient dilution standard curve and the clinical diagnosis and blood safety monitoring standardization requirements are met.

The objective is to provide novel anti-trypanosomal drugs useful for preventing or improving diseases caused by infection with Trypanosomiaceae protozoa. [Solution] 5-bromo-2-hydroxy-N-[2,5-bis(trifluoromethyl)phenyl]benzamide or a pharmacoposophicalally acceptable salt thereof, or 5-bromo-2-(morpholinocarbonyloxy)-N-[2,5-bis(trifluoromethyl)phenyl]benzamide is useful for the prevention or improvement of diseases caused by infection with Trypanosomiaceae protozoa.

This disclosure describes compounds of Formula I and Formula II, pharmaceutically acceptable salts or derivatives thereof, and pharmaceutical compositions thereof, useful in treating infections caused by parasitic protozoa, in particular protozoa of the genera Leishmania or Trypanosoma.

The application belongs to the technical field of molecular biology detection, and specifically relates to a Trypanosoma evansi qPCR detection method, which adopts a combination of specific primer pairs and a probe to perform real-time fluorescent quantitative PCR detection by a probe method; the combination of the primer pairs and the probe comprises an upstream primer ISG75-F, a downstream primer ISG75-R and a fluorescent probe ISG75-Probe; the nucleotide sequence of the upstream primer ISG75-F is shown in SEQ ID NO:1; the nucleotide sequence of the downstream primer ISG75-R is shown in SEQ ID NO:2; and the nucleotide sequence of the fluorescent probe ISG75-Probe is shown in SEQ ID NO:3. The Trypanosoma evansi qPCR detection method constructed by the application has high specificity of specific primer pairs and a probe, high sensitivity, good repeatability, simple operation, rapid detection, can realize qualitative and quantitative detection of Trypanosoma evansi, is suitable for clinical detection, epidemiological investigation, pathogen screening and treatment effect monitoring of Trypanosoma evansi disease of livestock and poultry and pets, and can be prepared into a commercial detection kit.

The invention provides a kit for detecting a trypanosoma kirschneri antibody, and relates to the technical field of biological detection. The kit for detecting the trypanosoma kirschneri antibody comprises a component A, a component B, a component C, a preserving fluid of the component A, a diluent of the component B and a diluent of the component C, the component A is a magnetic bead coated with a trypanosoma kirschneri antigen; the component B is avidin marked with a tracing marker; the component C is a trypanosoma kirschneri antigen marked with biotin; the preservation solution of the component A comprises a buffer solution containing bovine serum albumin; the diluent of the component B comprises a casein-containing buffer solution; the diluent of the component C comprises a buffer solution containing a surfactant. The kit is high in detection specificity, and can accurately detect the trypanosoma kirschisi antibody. The kit can also realize full-automatic chemiluminescence detection by virtue of a chemiluminescence immunoassay analyzer, so that the detection efficiency is improved, and manual operation errors are reduced.

The invention provides a modified Trypanosoma cruzi Tc24 polypeptide comprising an amino acid substitution at one or more of amino acid positions: 23, 98, 141, or any combination thereof, relative to the parent Trypanosoma cruzi Tc24 polypeptide. The invention further provides a diagnostic test comprising the modified Trypanosoma cruzi Tc24 polypeptide and a method of diagnosing an individual with Chagas disease using the diagnostic test of claim.

T, cruzi antigens that are useful for detection infection are provided. Methods of detection and various assay formats are also provided.

The present invention involves improving the expression of functional and stable recombinant proteins in mammalian expression systems using an oligosaccharide transferase (OST) enzyme obtained from Trypanosoma brucei. In particular, the present invention provides mammalian cells comprising at least one OST protein or at least one nucleic acid sequence encoding a functional fragment thereof, wherein the at least one OST protein is a Trypanosoma spp. OST protein, and preferably, the at least one OST protein is a Trypanosoma brucei OST protein.

The present invention belongs to the technical field of biological detection. Provided are a five-plex real-time fluorescent quantitative PCR detection kit and a detection method for the simultaneous detection of five parasites. The method and the kit can be used for simultaneously detecting Toxoplasma gondii, Neospora caninum, Eimeria stiedai, Giardia lamblia and Trypanosoma evansi in the same system; and have the characteristics of qualitative and quantitative detection capability, high sensitivity, strong specificity, good repeatability and good stability.

The present invention relates to a protein derived from the extracellular domain of the surface protein ISG65 (invariant surface glycoprotein 65 (Tbg.972.2.1600) of the human parasite Trypanosoma brucei gambiense. The ISG65-derived protein is useful in the treatment of complement dysregulation diseases. In one aspect, the present invention provides a novel thermostable mutant of ISG65.

Provided herein are compositions for increasing Apolipoprotein L1 (ApoL1) in target cells. The ApoL1 can be a recombinant protein or an endogenous protein optionally in a ApoL1-containing complex. Antibodies and other binding molecules that specifically bind, Apolipoprotein L1 (ApoL1) and Haptoglobin related protein (Hpr). In preferred embodiments, the antibodies and other molecules bind to an ApoL1-containing complex such as a Trypanosome Lytic Factor (TLF), preferably under physiological conditions. In preferred embodiments, the antibodies and antigen binding fragments are bispecific, trispecific, and multispecific molecules that can bind to the ApoL1-containing complex and further bind to a cell specific antigen. Methods of using such molecules to increase flux of ApoL1-containing complexes into target cells expressing the cell specific antigen are also provided. Such increase in ApoL-containing complexes can increase cell death. In preferred embodiments, the target cells are cancer cells such as blood cancer cells or solid tumor cells.